Effect of pulsatilla on polycystic ovarian syndrome and its associated cancer

  • Debpratim Chakraborty Jadavpur University
Keywords: PCOS, Endometrial cancer, Pulsatilla


Polycystic Ovarian Syndrome is one of the most common female endocrine. Many papers reported the correlation between infertility that most eminently predisposes towards cancer in PCOS women from many years. From both clinical and experimental research one can conclude that correlation between PCOS and endometrial cancer is the strongest. Most studies on correlation between PCOS and ovarian cancer as well as breast cancer failed to show a link though Pulsatilla have a strong effect on it. Various synthetic drugs which mainly used in the treatment of PCOS and endometrial cancer but here the problem is those drugs has lots of side effect/Adverse effect so we should go with the natural product Pulsatilla Sp. Which is used on PCOS and various cancer. Pulsatilla is a well establish drug for PCOS with unknown mechanism of action. Deoxypodophyllotoxin, which was isolated from the roots of P. koreana, was found to inhibit the tube-like formation of HUVECs (human umbilical venous endothelial cells) and have a potent antitumor effect. The chemical constituent saponin D present in Pulsatilla root is responsible for the anti tumor activity. The results, which are expressed as Pulsatilla saponin D has such a potent antitumor effect (IR, 82%) on a solid tumor, which is higher than Adriamycin (IR, 64%). 23-Hydroxybetulinic acid synthesized from Pulsatilla chinensis also shows anti tumoral activity. Though the potency of pulsatilla sp. are less than synthetic marketed drugs but by structural modification we may get potent anti canceral agent with least toxicity by Pulsatilla.

Author Biography

Debpratim Chakraborty, Jadavpur University

Department of Pharmacognosy,
Jadavpur University,
West bengal, India


1. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ 1986; 293; 355-359.
2. Brinton LA, Berman ML, Mortel R. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study Am J Obstet Gynecol. 1992; 167(5); 1317-1325.
3. Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Webb PM. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2007; 43(4); 690-709.
4. MacLaughlan SD, Palomino WA, Mo B, Lewis TD, Lininger RA, Lessey BA. Endometrial expression of Cyr61: a marker of estrogenic activity in normal and abnormal endometrium. Obstet Gynecol. 2007; 110(1); 146-154.
5. Villavicencio A, Bacallao K, Gabler F; Deregulation of tissue homeostasis in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia; Gynecol Oncol; 2007; 104(2); 290-295.
6. Gallup DG, Stock RJ; Adenocarcinoma of the endometrium in women 40 years of age or younger; Obstet Gynecol; 1984; 64(3); 417-420.
7. Jafari K, Javaheri G, Ruiz G; Endometrial adenocarcinoma and the Stein-Leventhal syndrome; Obstet Gynecol. 1978; 51(1); 97-100.
8. Schildkraut JM, Schwingl PJ, Bastos E; Epithelial ovarian cancer risk among women with polycystic ovary syndrome; Obstet Gynecol; 1996; 88(4 Pt 1); 554-559.
9. Gammon MD, Thompson WD; Polycystic ovaries and the risk of breast cancer; Am J Epidemiol; 1991; 134(8); 818-824.
10. Li, R. Z. and Ji, X. J.; The cytotoxicity and action mechanism of Ranunculin in vitro; Yao Xue Xue Bao; 1993; 28(5); 326-331.
11. Kim, S. Y. and Kim, S. B.; Anti-tumor effects of extracts of Pulsatilla koreana (SB-31®) in vitro; J. Kor. Cancer Assoc.; 1994; 26(6); 959-963.
12. Skehan P., Storeng R., Scudiero D; New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening; J. Natl. Cancer Inst. 1990; 82(13); 1107-1112.
13. Teruhiro U, Jiro S, Yoshikazu S; Antitumor activity of a novel podophylotoxin derivatives (TOP53) against lung cancer and lung matastatic cancer; Cancer Res; 1996; 56(12); 2809-2814.
14. Ji, Z., Ye, W., Liu, G., Hsiao, W; 23-Hydroxybetulinic acid-mediated apoptosis is accompanied by decreases in bcl-2 expression and telomerase activity in HL- 60 Cells; Life Sciences; 2002; 72(1), 1-9.
How to Cite
Chakraborty, D. 2018. Effect of pulsatilla on polycystic ovarian syndrome and its associated cancer. PharmaTutor. 4, 2 (Jun. 2018), 34-40.

Most read articles by the same author(s)